Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel vs Docetaxel Alone in Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized Phase III Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, With Docetaxel Versus Docetaxel in Advanced Non-Small-Cell Lung Cancer (GALAXY-2)
J. Clin. Oncol 2019 Dec 12;[EPub Ahead of Print], RN Pillai, DA Fennell, V Kovcin, TE Ciuleanu, R Ramlau, D Kowalski, M Schenker, I Yalcin, F Teofilovici, VM Vukovic, SS RamalingamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.